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(n¼113 lesions)
Retrograde
(n¼60 lesions) p value
Qualitative Findings:
Subintimal GW tracking, n
(%)*
18 (16) 33 (55) <0.001
Subintimal stenting, n (%) { 11 (9.7) 8 (13) 0.47
Dissection Flap, n (%) 39 (34.5) 42 (70) <0.001
Intramural Hematoma, n (%) 6 (5.3) 17 (28) <0.001
Calciﬁcation (%) 102 (90) 55 (92) 0.76
Calciﬁcation morphology
Superﬁcial (%) 67 (59) 38 (63) 0.6




12 (6 to 18) 17 (13 to 28) 0.01
Subintimal stenting length,
mm
13 (4 to 34) 12.6 (7 to 18) 0.93
Dissection length, mm 5.6 (4 to 9) 5.2 (3 to 9) 0.45
Maximum arc of calcium o 167 (110 to 239) 145 (96 to 194) 0.23
Proximal reference EEM
CSA, mm2
15.5  4.4 15.7  4.2 0.84
Proximal reference lumen
CSA, mm2
9.4  2.8 9.8  3.2 0.38
Distal reference-t EEM CSA,
mm2
8.4  3.4 7.6  2.9 0.15
Distal reference lumen CSA,
mm2
6  2 4.7  1.8 0.01
Post-Stent IVUS
measurements:
Mean stent CSA, mm2 7  1.9 6.7  1.9 0.47
Stent Expansion 0.86  0.33 0.91  0.27 0.34
Stent symmetry index 0.90  0.04 0.90  0.02 0.68
Values are n (%), mean  SD, or median (interquartile range). CSA ¼ cross-sectional area;
EEM ¼ external elastic membrane; GW¼ guidewire; IVUS ¼ intravascular ultrasound.
* immediately after wiring or after pre-dilation with a 1.5 to 2.0-mm balloon.{ ﬁnal guidewire
position in a false lumen with subsequent stent deployment in subintimal spaceConclusions: Intravascular ultrasound effectively differentiates between various GW
induced vessel injuries and depicts subintimal GW tracking. GW crossing with the
retrograde approach was associated with IVUS and angiographic coronary vessel
injuries, which increased the periprocedural complications. The long term clinical and
angiographic outcomes however, were comparable between the antegrade and retro-
grade approaches
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Background: The feasibility of using the BVS in chronic total occlusions (CTO)
lesions is unknown. This study sought to assess the safety, performance and efﬁcacy
of the Absorb everolimus-eluting bioresorbable vascular scaffold (BVS), in percuta-
neous CTO revascularization, under guidance of imaging techniques
Methods: 35 consecutive true CTOs lesions (Euro-CTO club deﬁnition) treated with
BVS were included in this prospective study. Target lesions were scaffold after
mandatory pre-dilatation and IVUS analysis. Optical coherence tomography (OCT)
study was performed after BVS implantation and at 12 months. A multi-slice
computed tomography (MSCT) was performed at baseline and at 6-8 months
Results: The mean age was 60.7  9.7 years old. 80% were male. 20% were diabetic
37% had a previous PCI. The most frequent lesions treated was the RCA (46%).
According to the Japanese-CTO score of complexity most of lesions were classiﬁed as
intermediate (49%) or difﬁcult-very difﬁcult (26%). 34% were moderate-severe
calciﬁed lesions. In most cases (86%) the strategy was antegrade. Pre-dilatation was
100% by cutting balloon in 71%. The total scaffold length implanted per lesion was ofB60 JACC Vol 64/11/Suppl B52.5  22.9mm. All the scaffolds were delivery and deployment successfully. Post-
dilatation was done in 63%. By OCT, ﬁnal minimum scaffold area and lumen stenosis
were of 7.1  1.5mm2 and 11.7  6.6%. There were no signiﬁcant areas of strut
malapposition. At a median of 10.2 (6.2-11.9) months, no MACE was reported and all
the devices were patent by MSCT. At 12-months angiographic follow-up with OCT
was completed in 16 patients, we observed one case of asymptomatic re-occlusion and
2 cases of signiﬁcant scaffold acquired malaposition.
Conclusions: BVS for CTO recanalization demonstrates excellent feasibility, safety
and long-term patency with no MACE at 10 months. At the time of the meeting
completed angiographic follow-up with OCT will be available
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Background: The “hybrid” approach to coronary chronic total occlusion (CTO)
crossing was developed to optimize procedural efﬁcacy, efﬁciency, and safety.
Methods: We examined the procedural techniques and outcomes of 639 consecutive
CTO percutaneous coronary interventions (PCI) performed using the “hybrid”
approach between 2012 and 2014 at 6 US centers.
Results: Mean age was 65  10 years and 86% of the patients were men, with high
prevalence of diabetes mellitus (42%) and prior coronary artery bypass graft surgery
(36%). Most target CTOs were located in the right coronary artery (59%), followed by
the left anterior descending artery (20%) and left circumﬂex (14%). Dual injection was
used in 74%. Overall, antegrade wire escalation was used in 65%, antegrade dissection/
re-entry in 38%, and the retrograde approach in 44%. Among successful cases, the ﬁnal
successful crossing technique was antegrade wire escalation in 42%, antegrade dissection
and re-entry in 27%, and retrograde in 31%. The initial crossing strategy was successful
in 60% of the patients, whereas 40% required an additional 1 to 4 crossing strategies.
Technical success was achieved in 92.6% and a major procedural complication occurred
in 1.7%. Median contrast volume, ﬂuoroscopy time, and air kerma radiation exposure
were 260 (190-360) ml, 42 (26-69) min, and 3.8 (2.2-5.8) Gray, respectively.
Conclusions: Application of the “hybrid” approach to CTO crossing resulted in high
success and low complication rates among a varied operator group and hospital
structure, supporting its expanding use in CTO PCI.
TCT-205
Mid-term angiographic and clinical outcomes of controlled antegrade and
retrograde subintimal tracking (CART) or reverse CART technique for the
recanalization of chronic total occlusions
Akiko Fujino1, Satoru Otsuji1, Katsuyuki Hasegawa1, Shin Takiuchi1,
Katsuaki Asano1, Munemitsu Ibuki1, Shinya Nagayama1, Kasumi Ishibuchi1,
Toshikazu Kashiyama1, Daisuke Shishikura1, Rui Ishii1, Masanori Yabuki1,
Yorihiko Higashino1
1Higashi-Takarazuka Satoh Hospital, Takarazuka, Japan
Background: Although controlled antegrade and retrograde subintimal tracking
(CART) and reverse CART techniques improve the success rate of percutaneous
coronary intervention (PCI) for coronary chronic total occlusions (CTO), the safety
and efﬁcacy of these techniques have not yet been fully evaluated.
Methods: We studied 321 consecutive patients who were performed successful stent
implantation for de novo CTO lesion in our hospital between 2008 and 2013. After
excluding patients who were not performed follow-up coronary angiography after
PCI, ﬁnally 253 patients were examined. Patients were categorized as treated CTO
with CART or reverse CART technique group (CART group: n¼30) versus the
conventional treatment group (control group; n¼223). Angiographic and clinical
outcomes at 8-12 months were compared between the two groups.
Results: At baseline, the occlusion length was signiﬁcantly longer in patients in the
CART group (2117mm vs. 1310mm, p< 0.001) and the mean reference diameter
of the lesion was similar between the two groups (2.700.44mm vs. 2.810.48mm,
p¼0.33). The rate of complication including wire perforation or local dissection of the
coronary artery in the CART group was signiﬁcantly higher than the control group
(17% vs. 4%, p< 0.01). At the 8 to 12 months, there was no signiﬁcant differences in
the restenosis rate (13% vs 13%, p¼0.96). In addition, there was no statistical dif-
ferences between the two groups in angiographic parameters such as minimum lumen
diameter (2.380.86mm vs. 2.340.76mm, p¼0.85), percent diameter stenosis
(1927% vs. 1822%, p¼0.84) and late lumen loss (0.360.70mm vs
0.640.94mm, p¼0.11). During 8-month follow-up after PCI, no difference was
observed between the two groups in terms of major adverse cardiac events (MACEs)j September 13–17, 2014 j TCT Abstracts/Coronary Lesions - CTO
